Illumina (ILMN) Optics for Genomics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics

ILMN 123.54

+24.8%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: JakeStraw	1/19/2017 10:07:54 AM
	Read Replies (1) of 276

While Illumina (NASDAQ:ILMN) shares have mounted a solid rally recently off of good news from the JP Morgan Healthcare conference, shares are still down around 6% over the last year. However, recent news regarding a competing company may be a glimmer of hope for this giant of genomics. Last month, Pacific Biosciences of California, Inc (NASDAQ:PACB) announced that pharma giant Roche (NASDAQOTH:RHHBY) had elected to terminate its development, commercialization, and license agreement for the development of supply diagnostic products with Pacific Biosciences. As Pacific Biosciences is one of only a handful of companies which operate within the genome sequencing market, this blow for Pacific Biosciences could provide a boon for Illumina's future market dominance. fool.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next